Johnson & Johnson Q2 Earnings Beat Led By A Solid Growth In Oncology Drug Sales

Johnson & Johnson (NYSE:JNJ) recently posted a better than expected Q2 performance with an 11% jump in sales, led by a ramp up in Oncology drugs - Darzalex, Imbruvica, and Zytiga. The company's Medical Devices segment also saw a low single digit revenue growth, led by Vision Care. The company...